Stage 4 | |||||||
---|---|---|---|---|---|---|---|
MT | TT | p Value | CPA≥6% | CPA≥7.2% | HVPG≥10 mm Hg | Decompensation | |
Cold/warm ischaemia time (min) | 680/46 | 688/41 | NS | NS | NS | NS | NS |
Treatment allocation (evaluated) | 54 (49) | 49 (48) | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
Stopped azathioprine | NA | 16 (33%) | <0.001 | <0.001 | <0.001 | 0.012 | 0.013 |
Tacrolimus trough concentrations (ng/mL) | |||||||
5 days | 7.7 | 5 | 0.002 | 0.002 | 0.01 | 0.017 | 0.01 |
15 days* | 8.5 | 6.1 | 0.003 | 0.001 | 0.01 | 0.001 | 0.01 |
30 days* | 7.9 | 6.7 | 0.01 | 0.01 | 0.04 | 0.02 | 0.01 |
Conc. HCC | 17 | 13 | NS | NS | NS | NS | 0.03 |
Conc. ALD | 10 | 12 | NS | NS | NS | NS | NS |
Age | 48.9 years | 50 years | NS | NS | NS | NS | NS |
Donor age | 48.5 years | 44 years | 0.01 | 0.01 | 0.01 | 0.04 | 0.02 |
Gender mismatch | 17 | 17 | NS | NS | NS | NS | NS |
Rejection episodes | 42 | 64 | 0.002 | 0.0033 | 0.04 | 0.033 | NS |
Rejection treatment (courses) | 21 | 30 | 0.002 | 0.01 | 0.03 | 0.038 | NS |
HDNH | 17 | 8 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
CMV viraemia treated | 7 | 10 | NS | NS | NS | NS | NS |
Viral load logIU/mL (median) | |||||||
Pre-LT | 5.29 | 5.36 | NS | NS | NS | NS | NS |
3 m post-LT | 6.6 | 6.39 | NS | NS | NS | NS | NS |
Genotype 1/1b | 41% | 41% | NS | NS | NS | NS | NS |
Antiviral treatment | 19 | 11 | 0.01 | 0.01 | 0.01 | 0.001 | 0.001 |
SVR | 3 | 3 | NS | NA | NA | NA | NA |
DM | |||||||
Pre-LT | 13 | 13 | NS | NS | NS | NS | NS |
Post-LT (last follow-up) | 19 | 15 | 0.013 | 0.038 | 0.044 | NS | NS |
*Median trough levels derived from all measurements up to days 15 and 30 post-LT.
ALD, alcoholic liver disease; CMV, cytomegalovirus; CPA, collagen proportionate area; DM, diabetes mellitus; HCC, hepatocellular carcinoma; HDNH, histological de novo hepatitis; HVPG, hepatic venous pressure gradient; LT, liver transplantation; MT, monotherapy; NA, non-applicable; NS, non-significant; SVR, sustained virological response; TT, triple therapy.